Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10,963Revenue $M2,617Net Margin (%)-54.2Z-Score0.6
Enterprise Value $M14,659EPS $-6.1Operating Margin %-58.5F-Score4
P/E(ttm))0Cash Flow Per Share $7.2Pre-tax Margin (%)-66.9Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %0Quick Ratio1.1Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %0Current Ratio1.3Lower Leverage y-yN
Price/Cash Flow3.9y-y EBITDA Growth Rate %0ROA % (ttm)-16.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-71.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M154ROI % (ttm)-16.6Gross Margin Increase y-yN

Gurus Latest Trades with ENDP

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ENDPJohn Griffin 2014-09-30 Reduce-0.77%$61.26 - $70.27
($65.73)
$ 71.318%Reduce -16.38%5,698,528
ENDPWallace Weitz 2014-09-30 Reduce-0.34%$61.26 - $70.27
($65.73)
$ 71.318%Reduce -17.65%721,950
ENDPJoel Greenblatt 2014-09-30 Reduce-0.07%$61.26 - $70.27
($65.73)
$ 71.318%Reduce -84.54%13,716
ENDPWallace Weitz 2014-06-30 Add0.81%$56.28 - $73.94
($66.81)
$ 71.317%Add 75.01%876,670
ENDPJoel Greenblatt 2014-06-30 Buy 0.08%$56.28 - $73.94
($66.81)
$ 71.317%New holding, 88697 sh.88,697
ENDPMario Gabelli 2014-06-30 Reduce$56.28 - $73.94
($66.81)
$ 71.317%Reduce -21.77%23,900
ENDPSteve Mandel 2014-06-30 Sold Out -1.2%$56.28 - $73.94
($66.81)
$ 71.317%Sold Out0
ENDPJohn Griffin 2014-06-30 Reduce-0.9%$56.28 - $73.94
($66.81)
$ 71.317%Reduce -14.81%6,815,000
ENDPGeorge Soros 2014-06-30 Sold Out -0.13%$56.28 - $73.94
($66.81)
$ 71.317%Sold Out0
ENDPJulian Robertson 2014-03-31 Buy 0.51%$64.3 - $81.49
($70.78)
$ 71.311%New holding, 22800 sh.22,800
ENDPGeorge Soros 2014-03-31 Buy 0.13%$64.3 - $81.49
($70.78)
$ 71.311%New holding, 198503 sh.198,503
ENDPWallace Weitz 2014-03-31 Add0.12%$64.3 - $81.49
($70.78)
$ 71.311%Add 12.33%500,920
ENDPJoel Greenblatt 2014-03-31 Sold Out -0.64%$64.3 - $81.49
($70.78)
$ 71.311%Sold Out0
ENDPRay Dalio 2014-03-31 Sold Out -0.01%$64.3 - $81.49
($70.78)
$ 71.311%Sold Out0
ENDPDavid Dreman 2014-03-31 Sold Out -0.01%$64.3 - $81.49
($70.78)
$ 71.311%Sold Out0
ENDPSteve Mandel 2013-12-31 Buy 1.3%$43.64 - $67.25
($57.05)
$ 71.3125%New holding, 4340000 sh.4,340,000
ENDPWallace Weitz 2013-12-31 Buy 1%$43.64 - $67.25
($57.05)
$ 71.3125%New holding, 445920 sh.445,920
ENDPJohn Griffin 2013-12-31 Add0.7%$43.64 - $67.25
($57.05)
$ 71.3125%Add 14.29%8,000,000
ENDPDavid Dreman 2013-12-31 Buy 0.01%$43.64 - $67.25
($57.05)
$ 71.3125%New holding, 1378 sh.1,378
ENDPAndreas Halvorsen 2013-12-31 Sold Out -0.81%$43.64 - $67.25
($57.05)
$ 71.3125%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ENDP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ENDP - CALLJohn Griffin 2014-09-30676,6000.440.55
ENDP Mario Gabelli 2014-09-3022,9000.010.01-4.18%
ENDP Julian Robertson 2014-09-3020,3000.010.37-10.96%
ENDP John Griffin 2014-09-305,698,5283.714.6-16.38%
ENDP Wallace Weitz 2014-09-30721,9500.471.5-17.65%
ENDP Joel Greenblatt 2014-09-3013,7160.010.01-84.54%
Premium Most recent portfolio changes are included for Premium Members only!


ENDP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Upadhyay SuketuEVP, CFO 2014-11-14Buy3,700$66.941.46view
HIGGINS ARTHUR JDirector 2014-08-05Buy3,500$65.653.46view
DELUCCA JOHNDirector 2014-06-09Sell6,764$68.83-1.32view
MANOGUE CAROLINE BExec. V.P., CLO & Secy 2014-05-29Sell175,033$72.02-5.69view
DELUCCA JOHNDirector 2014-05-01Sell8,094$66.312.43view
DELUCCA JOHNDirector 2014-04-01Sell10,384$68.46-0.79view
Gergel Ivan P.EVP, R&D and CSO 2014-03-10Sell75,637$72.47-6.28view
HIGGINS ARTHUR JDirector 2014-03-10Buy5,000$73-6.96view
Hutson Nancy JDirector 2014-03-10Sell5,000$72.12-5.82view
MANOGUE CAROLINE BExec. V.P., CLO & Secy 2013-08-26Sell145,592$39.472.39view

Press Releases about ENDP :

    Quarterly/Annual Reports about ENDP:

    News about ENDP:

    Articles On GuruFocus.com
    Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector Dec 01 2014 
    Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
    H/C -- winner. Down Mar 02 2013 
    greenblatt - low Jan 22 2013 
    comment on ENDP Nov 28 2012 
    comment on ENDP Jul 09 2012 
    Weekly Top Insider Buys: MDT, KMI, WIN, ENDP, OC Jun 25 2012 
    Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP Jun 16 2012 
    Endo Pharmaceuticals Holdings Inc. (ENDP) EVP, CFO Alan G Levin sells 16,627 Shares Dec 09 2010 
    Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) Nov 02 2010 


    More From Other Websites
    Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
    Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
    Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
    Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel Dec 09 2014
    Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel Dec 09 2014
    Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel Dec 09 2014
    ENDO INTERNATIONAL PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 03 2014
    Trimel Announces Exclusive License Agreement With Endo For Natesto™ Nov 24 2014
    Endo Acquires Rights to Natesto™ Testosterone Nasal Gel Nov 24 2014
    Endo Acquires Rights to Natesto™ Testosterone Nasal Gel Nov 24 2014
    Endo Acquires Rights to Natesto™ Testosterone Nasal Gel Nov 24 2014
    U.S. court denies Ranbaxy's bid to block launch of rival generics Nov 20 2014
    U.S. court denies Ranbaxy's bid to block launch of rival generics Nov 20 2014
    U.S. court denies Ranbaxy's bid to block launch of rival generics Nov 20 2014
    Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 20 2014
    Endo Announces Launch of Generic Version of Valcyte® Nov 20 2014
    Endo Announces Launch of Generic Version of Valcyte® Nov 20 2014
    U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs Nov 20 2014
    Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 19 2014
    Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK